India, Dec. 17 -- Lupin on Wednesday said it has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (USFDA) for its injectable manufacturing facility in Nagpur.
The EIR was issued following an inspection conducted from September 8 to September 16, 2025. A VAI classification indicates that while certain objectionable conditions were observed, the USFDA does not intend to take or recommend any regulatory or administrative action at this stage.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....